Guidance for Industry: Standards for Clinical Trials in Type 2 Diabetes in Canada

Health Canada is issuing this guidance for clinical trials in type 2 diabetes to provide clarification on the interpretation of the Canadian Diabetes Association Clinical Practice Guidelines (CDA-CPG)Footnote1 in relation to clinical trial applications under Part C, Division 5 of the Food and Drug Regulations.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Ligne directrice : Normes applicables aux essais cliniques sur le diabète de type 2 au Canada
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2007-09-04 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["lignes directrices pour l'industrie", "normes", "essais cliniques sur le diabète de type 2", "lignes directrices de pratique clinique de l'Association canadienne du diabète", "CDA-CPG", "Règlement sur les aliments et drogues"], "en": ["guidance for industry", "standards", "clinical trials in type 2 diabetes", "Canadian Diabetes Association Clinical Practice Guidelines", "CDA-CPG", "Food and drug Regulations"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source